Turning cutting-edge innovations into breakthrough Biotech companies
Argobio is a start-up studio dedicated to novel therapeutics aiming to nurture and launch breakthrough Biotech companies. Argobio sources innovative early-stage projects from renowned European academic research institutions with the objective of incubating these projects before company creation. The focus is on rare diseases, neurological disorders, oncology, and immunology. The studio also look to develop promising platform technologies for therapeutic products.
Argobio was initiated by Kurma Partners, Bpifrance, Angelini Pharma, Evotec and Institut Pasteur who have committed 50M € to Argobio.
Turning cutting-edge innovations into breakthrough Biotech companies
https://www.argobiostudio.com/
Argobio is a start-up studio dedicated to novel therapeutics aiming to nurture and launch breakthrough Biotech companies. Argobio sources innovative early-stage projects from renowned European academic research institutions with the objective of incubating these projects before company creation. The focus is on rare diseases, neurological disorders, oncology, and immunology. The studio also look to develop promising platform technologies for therapeutic products.
Argobio was initiated by Kurma Partners, Bpifrance, Angelini Pharma, Evotec and Institut Pasteur who have committed 50M € to Argobio.
Argobio SAS is a newly-created START-UP STUDIO dedicated to novel Therapeutics aiming to nurture and launch at least five breakthrough Biotech companies over the next five years.Argobio will source innovative early-stage projects from renowned European academic research institutions. The focus is on selected therapeutic areas, including rare diseases, neurological disorders, oncology, and immunology. The studio will also look to develop promising platform technologies for therapeutic products.Argobio will identify, select, and incubate these projects up to company creation and beyond, providing broad expertise in the discovery and development of novel drugs with a team of highly experienced Biotech entrepreneurs. The internal team is led by Yves Ribeill, Neill Mackenzie, Poul Sørensen and Rémi Soula. Thierry Laugel, Managing Partner at Kurma Partners is the President of Argobio. Argobio was initiated by Kurma Partners, a leading Paris-based healthcare venture capital firm, and Bpifrance, the French national investment bank. Kurma and Bpifrance were joined by complementary strategic investors, Angelini Pharma, a private international pharmaceutical company, Evotec, a drug discovery alliance and development partnership company, and the Institut Pasteur, internationally renowned center for biomedical research._en
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 19 Apr 2024 | | |
Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 29 Jun 2023 | |